TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β
Open Access
- 7 July 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 98 (5) , 703-712
Abstract
DGK-ζ is a negative regulator of TCR signaling that causes degradation of the second messenger DAG, terminating DAG-mediated activation of Ras and PKCθ. Cytotoxic T cells deficient in DGK-ζ demonstrate enhanced effector functions in vitro and antitumor activity in vivo, perhaps because of insensitivity to inhibitory cytokines. We sought to determine whether the enhanced responsiveness of DGK-ζ-deficient T cells renders them insensitive to the inhibitory cytokine TGF-β and to determine how the loss of DGK-ζ facilitates this insensitivity. We identified decreased transcriptional and functional responses to TGF-β in CD8+ DGK-ζ−/− T cells but preserved TGF-β-mediated conversion of naϊve DGK-ζ−/− CD4+ T cells to a regulatory T cell phenotype. Decreased CD8+ T cell responsiveness to TGF-β did not result from impaired canonical TGF-β signal transduction, because similar levels of TGF-β-R and intracellular Smad components were identified in WT and DGK-ζ−/− CD8+ T cells, and TGF-β-mediated activation of Smad2 was unchanged. Instead, an enhanced TCR signal strength was responsible for TGF-β insensitivity, because (i) loss of DGK-ζ conferred resistance to TGF-β-mediated inhibition of Erk phosphorylation, (ii) TGF-β insensitivity could be recapitulated by exogenous addition of the DAG analog PMA, and (iii) TGF-β sensitivity could be observed in DGK-ζ-deficient T cells at limiting dilutions of TCR stimulation. These data indicate that enhanced TCR signal transduction in the absence of DGK-ζ makes T cells relatively insensitive to TGF-β, in a manner independent of Smads, a finding with practical implications in the development of immunotherapies that target TGF-β.Keywords
Funding Information
- National Institutes of Health (K08-CA151893)
- American Cancer Society
- Medical College of Wisconsin Cancer
- M.J.R.
- Blood Research Institute
- Blood Center of Wisconsin
- Blood Research Institute, Blood Center of Wisconsin
This publication has 34 references indexed in Scilit:
- Diacylglycerol Kinases: Regulated Controllers of T Cell Activation, Function, and DevelopmentInternational Journal of Molecular Sciences, 2013
- Releasing the Brake: Targeting Cbl-b to Enhance Lymphocyte Effector FunctionsJournal of Immunology Research, 2012
- Decreased Diacylglycerol Metabolism Enhances ERK Activation and Augments CD8+ T Cell Functional ResponsesJournal of Biological Chemistry, 2011
- Smad2 and Smad3 Are Redundantly Essential for the TGF-β–Mediated Regulation of Regulatory T Plasticity and Th1 DevelopmentThe Journal of Immunology, 2010
- Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune CellsClinical Cancer Research, 2010
- Transforming growth factor beta (TGF-β) and inflammation in cancerCytokine & Growth Factor Reviews, 2010
- The regulation of TGFβ signal transductionDevelopment, 2009
- TGF-β modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expressionCancer Immunology, Immunotherapy, 2009
- ‘Yin–Yang’ functions of transforming growth factor‐β and T regulatory cells in immune regulationImmunological Reviews, 2007
- Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory diseaseNature, 1992